1. Cytoskeleton
    Autophagy
    Apoptosis
  2. Integrin
    Autophagy
    Apoptosis
  3. OSU-T315

OSU-T315 

Cat. No.: HY-18676 Purity: 99.88%
Handling Instructions

OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner. OSU-T315 causes cell death through apoptosis and autophagy.

For research use only. We do not sell to patients.

OSU-T315 Chemical Structure

OSU-T315 Chemical Structure

CAS No. : 2070015-22-2

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 493 In-stock
Estimated Time of Arrival: December 31
2 mg USD 240 In-stock
Estimated Time of Arrival: December 31
5 mg USD 420 In-stock
Estimated Time of Arrival: December 31
10 mg USD 600 In-stock
Estimated Time of Arrival: December 31
50 mg USD 1800 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 4 publication(s) in Google Scholar

Top Publications Citing Use of Products

    OSU-T315 purchased from MCE. Usage Cited in: Cancer Sci. 2019 May;110(5):1804-1813.

    Effect of OSU-T315 on the proportion of ALDH-hi cells (left and middle) and the ALDH1A1 and SDPR protein level in EV HEC-108 cells (right). Equal protein loading is confirmed by quantifying β-actin (input control).
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain)[1]. OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner[2]. OSU-T315 causes cell death through apoptosis and autophagy[1].

    IC50 & Target

    IC50: 0.6μM; Integrin-linked kinase (ILK) inhibitor[1]

    In Vitro

    OSU-T315 (Compound 22; 0-5 μM; 24 hours) exhibits high in vitro potency against a panel of prostate and breast cancer cell lines with a IC50 range of 1-2.5 μM[1].
    OSU-T315 (0-4 μM; 24 hours) can reduce YB-1, HER2, and EGFR expression; shows a modest suppressive effect on phosphorylated S6 levels, exhibits dose-dependent suppressive effects on the levels of phospho-ERK1/2 and phospho-p38, while that of phospho-JNK remains unaltered in PC-3 cell[1].
    OSU-T315 (0-4 μM; 24 hours) causes autophagy through ILK inhibition[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay [1]

    Cell Line: Prostate cancer cells: LNCaP, PC-3; breast cancer cells: MDA-MB-231, MDA-MB-468, SKBR3, MCF-7; PrEC and MEC cells
    Concentration: 0-5 μM
    Incubation Time: 24 hours
    Result: Suppressed cancer cells viability in breast and prostate cancer cells (IC (50), 1-2.5μM).

    Western Blot Analysis [1]

    Cell Line: PC-3 cells; MDA-MB-231 cells
    Concentration: 1 μM, 2 μM, 3 μM, 4 μM; 0.5 μM, 1 μM, 1.5 μM, 2 μM, 2.5 μM
    Incubation Time: 24 hours
    Result: Exhibited a dose-dependent decreasing effect on the phosphorylation of pS6, ERKs, and p38 in PC-3 cells and MDA-MB-231 cells.

    Apoptosis Analysis[1]

    Cell Line: PC-3 cells
    Concentration: 1 μM, 2 μM, 3 μM, 4 μM
    Incubation Time: 24 hours
    Result: Induced accumulation of LC3-II and PARP cleavage.
    In Vivo

    OSU-T315 (Oral gavage; 25 mg/kg, 50 mg/kg; single daily; 35 days) has a suppressive effect of on PC-3 xenograft tumor growth [1].
    No other obvious toxicity is observed in mice[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male NCr athymic nude mice with PC-3 tumor xenografts
    Dosage: 25 mg/kg; 50 mg/kg
    Administration: Oral gavage; single daily; 35 days
    Result: Resulted in suppression of tumor growth relative to the vehicle control after 35 days of treatment (48% and 62% suppression for 25 and 50 mg/kg, respectively).
    Molecular Weight

    533.59

    Formula

    C₃₀H₃₀F₃N₅O

    CAS No.

    2070015-22-2

    SMILES

    O=C(NC)CCC1=CC(C2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)=NN1C4=CC=C(N5CCNCC5)C=C4

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 50 mg/mL (93.70 mM)

    H2O : < 0.1 mg/mL (insoluble)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.8741 mL 9.3705 mL 18.7410 mL
    5 mM 0.3748 mL 1.8741 mL 3.7482 mL
    10 mM 0.1874 mL 0.9370 mL 1.8741 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.17 mg/mL (4.07 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.17 mg/mL (4.07 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References

    Purity: 99.88%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    OSU-T315IntegrinAutophagyApoptosisInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email address *

    Phone number *

     

    Organization name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    OSU-T315
    Cat. No.:
    HY-18676
    Quantity:
    MCE Japan Authorized Agent: